AT WHAT COST? ‹ Back to dashboard
{{ bill.code }} · {{ bill.congressLabel }} {{ bill.tag }}
{{ bill.title }}
{{ bill.summary }}
{{ bill.status }}{{ bill.pct }}
{{ bill.latestAction }}
{{ bill.cosponsorCount }}
co-sponsors {{ bill.cosponsorCaret }}
{{ bill.congressNum }}th
Congress
Read full text →
on Congress.gov
Co-sponsors
{{ cs.name }} {{ cs.tag }}
Individual co-sponsor names aren't available yet for this bill — only the total count.
What it actually does
{{ p.sec }}
{{ p.title }}
{{ p.body }}
Where it's been — and where it's stuck
{{ t.title }}
{{ t.date }}
{{ t.note }}
Who's for it, who's blocking it
Latest committee vote. Tap a name for their full record.
FOR
— protects constituents
AGAINST
— sided with pharma lobby
Who's spending to kill it
Lobbying against H.R.882 in the last cycle.
{{ m.amount }}
{{ m.name }}
{{ m.note }}
Lies vs. truth about this bill
The claim
"Capping insulin at $35 will cause shortages and gut research into new drugs."
— floor remarks, illustrative
What the record says
CBO scores the cap as net-zero to taxpayers and projects no shortage. Industry filings show R&D is a small fraction of marketing spend. Medicare's existing $35 cap produced no shortage.
— CBO score + 10-K filings, illustrative
Rating: False
Push it over the line
It's one floor vote away. Tell the holdouts where you stand.
Bill data: Congress.gov · CBO · FEC · OpenSecrets. "Greater Good" tag and ratings are At What Cost's own editorial judgment. Illustrative sample data.